Skip to content

The eHealth Diabetes Remission Trial

eHealth Diabetes Remission Trial (Swedish: Remission av Typ 2 Diabetes Med hjälp av eHälsa

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05491005
Acronym
eDIT
Enrollment
106
Registered
2022-08-08
Start date
2022-08-31
Completion date
2026-12-31
Last updated
2024-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2

Keywords

Diabetes Remission, Nutrition Therapy, Obesity, eHealth, Weight Loss

Brief summary

Overweight patients with type 2 diabetes are offered a total diet replacement with the goal of weight loss and diabetes remission. Study participants are randomised to eHealth follow-up or face-to-face follow-up, but the dietary advice is the same in both groups. A healthy control group with normal glucose tolerance is examined once but is not randomised and does not receive any intervention.

Detailed description

One hundred and six overweight patients with type 2 diabetes replace usual foods with total diet replacement (850 kcal/day) for 3 months with the goal of 15 kg weight loss and diabetes remission (HbA1c \< 48 mmol/mol without diabetes medication). After 3 months of total diet replacement, food is reintroduced stepwise, and an individually tailored energy prescription is used to prevent weight regain. If study participants do not reach the weight loss goal at 3 months, they are recommended two additional months of total diet replacement. If weight regain occurs during the weight maintenance phase, a rescue plan with total diet replacement will be recommended. To increase the chances to maintain their lower body weight, participants will use a program specifically design for that purpose based on cognitive behavioural therapy. Total study duration is two years. The one hundred and six participants are randomised to either the eHealth follow-up or the face-to-face follow-up. The dietary advice to achieve and maintain weight loss is the same in both groups and delivered by the same dietician, physician, and nurse but the method of follow-up differs between groups (eHealth vs face-to-face). eHealth group: All study information and the cognitive behavioural therapy program is given by an eHealth application in Stöd och behandling which is part of 1177.se. Participants register body weight, fasting blood glucose, and blood pressure every morning at 1177.se. Regularly a measurement of HbA1c is taken at home. Participants will have scheduled video appointments with the study dietician, study nurse or study physician. Face-to-face group: Participants have appointments in the medical office with the study physician/nurse/dietician. At the appointments, body weight, blood pressure and capillary blood glucose is measured. HbA1c is measured during the appointments at 0, 6, 12 and 24 months. The cognitive behavioral therapy program for the control group is identical to the program of the intervention group, but the program is delivered during the face-to-face appointments. Healthy control group: Fifteen healthy participants with normal glucose tolerance, stable body weight for at least one year and matched to the study participants for sex, age, and weight after one year study duration, will be examined once. These participants are not randomised and do not receive any intervention. Outcomes: Primary and secondary outcome measures are compared between 1) the experimental eHealth group and 2) the experimental face-to-face group. For the other pre-specified outcome measures the experimental eHealth group and the experimental face-to-face group are taken together as one group, examined twice (baseline and 12 months) and compared to the healthy control group, that is examined only once. Long-term follow-up: Because long term data on diabetes remission by total diet replacement are lacking, study participants will be followed after they have finished the study. Data of the national diabetes registry from participants of this study will be compared to other patients in the national diabetes registry not participating in this study but matched for age, sex and diabetes duration to the study participants.

Interventions

Total diet replacement (850 kcal/day) for 3 months followed by weight maintenance for 21 months.

BEHAVIORALeHealth

All follow-up through an eHealth application and video meetings.

BEHAVIORALFace-to-face

All follow-up through face-to-face meetings.

Sponsors

Region Västerbotten
CollaboratorOTHER_GOV
Edgar Sjölunds Diabetes Foundation
CollaboratorUNKNOWN
Umeå University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Type 2 diabetes with duration 0-6 years * BMI 27 kg/m2 and higher * HbA1c 43 mmol/mol or higher (48 or higher if without diabetes medication)

Exclusion criteria

* Insulin treatment * Weight loss more than 5 kg during the past 6 months * Diagnosed eating disorder * eGFR \< 30 ml/min/1,73m2 * Myocardial infarction last six months * Severe heart failure (NYHA class III) * Ongoing cancer * Pregnancy * Treatment with antipsychotic drugs

Design outcomes

Primary

MeasureTime frameDescription
HbA1c12 monthsHbA1c without diabetes medication as a continuous outcome (HbA1c correction according to Tsapas et al 2020 if on diabetes medication). The outcome will be tested for non-inferiority first, with a non-inferiority margin of 8 mmol/mol; followed by a test for superiority.

Secondary

MeasureTime frameDescription
Quality of life according to EQ-5D-5L6, 12, 24 monthsThe questionnaire investigates the dimensions mobility, self-care, usual activities, pain and anxiety/depression. Minimum value 1. Maximum value 5. A higher score means a worse outcome. In addition, a general health score is assessed. Minimum value 0. Maximum value 100. A higher score means a better outcome. All dimension will be analysed separately, but EQ-5D-5L will also be combined to one score.
Body weight6, 12 and 24 monthsBody weight as a continuous outcome
Achieved weight loss of at least 15 kg6, 12 and 24 monthsNumber of participants with achieved weight loss of at least 15 kg
Number of participants that discontinue the intervention6, 12, 24 months
HbA1c follow-upYearly up to 20 yearsCollected from patient journals after study completion
Incremental costs per diabetes remission24 months
Estimated lifetime costs24 months
Estimated lifetime costs per quality-adjusted life-year (QALY)24 months
Fasting blood glucose6, 12, 24 monthsPartial diabetes remission (\<7.0 mol/l), complete diabetes remission (\<6.1 mol/l) without diabetes medication.
P-glucose 120 minutes after the oral glucose tolerance test6, 12, 24 months
Number of prescribed oral anti diabetic medications6, 12, 24 months
Number of prescribed antihypertensive medications6, 12, 24 months
Blood pressure (systolic/diastolic)6, 12, 24 monthsMeasured at the research facilities
Blood pressure6, 12, 24 months24h monitoring
Plasma lipid profile6, 12, 24 months
Waist circumference6, 12, 24 months
Relation to food6, 12, 24 monthsThree factor eating questionnaire
Estimation of exhaustion6, 12, 24 monthsKarolinska Exhaustion Disorder Scale. Minimum value 0. Maximum value 54. A higher score means a worse outcome.
Quality of life accoring to Brunnsviken Brief Quality of Life Scale6, 12, 24 monthsThe scale estimates how satisfied the participants is with different areas of life, as well as how important each area of life is. Minimum scale 0. Maximum scale 48. A higher score means a better outcome.
Eating habits6, 12, 24 monthsFFQ 2020 questionnaire
Estimation of health6, 12, 24 monthsSF-36 questionnaire
Blood pressure follow-upYearly up to 20 yearsCollected from patient journals after study completion
Usage of diabetes medication follow-upYearly up to 20 yearsCollected from patient journals after study completion
Usage of hypertension medication follow-upYearly up to 20 yearsCollected from patient journals after study completion
Diabetes complications follow-upYearly up to 20 yearsCollected from patient journals and registries after study completion
Body weight follow-upYearly up to 20 yearsCollected from patient journals after study completion
Daily steps6, 12, 24 monthsMeasured with activity tracker
Study experience24 monthsQualitative questions with written answers about study experience
Liver enzymes6, 12, 24 monthsAST, ALT
HbA1c6 and 24 monthsHbA1c without diabetes medication as a continuous outcome (HbA1c correction according to Tsapas et al 2020 if on diabetes medication). The outcome will be tested for non-inferiority first, with a non-inferiority margin of 8 mmol/mol; followed by a test for superiority.
Diabetes remission6, 12 and 24 monthsNumber of participants with HbA1c \< 48 mmol/mol without diabetes medication. The outcome will be tested for non-inferiority first with a non-inferiority margin of 10 percentage points; followed by a test for superiority.

Other

MeasureTime frameDescription
Urine albumin to creatinine ratio6, 12, 24 months
Slow vital capacity (SVC)12 monthsSpirometry
Secretion of adipokines, metabolites and lipids in subcutaneous fat cells ex vivo12 months
Plasma testosterone levels6, 12 and 24 monthsOnly men
Insulin sensitivity12 monthsHyperinsulinemic euglycemic clamp
Insulin secretion12 monthsStepped insulin secretion test with arginine
Metabolic flexibility12 monthsHyperinsulinemic euglycemic clamp
Resting metabolic rate12 monthsIndirect calorimetry
Body composition12 monthsDual-energy X-ray absorptiometry (DXA).
Glucagon sensitivity12 monthsPlasma amino acids are measured during 120 minutes after a intravenous glucagon bolus
Amino acid tolerance12 monthsPlasma amino acids are measured during intravenous amino acid infusion
Glucagon secretion capacity12 monthsPlasma glucagon is measured during intravenous amino acid infusion
Gut hormones after carbohydrate intake6, 12, 24 monthsGLP-1, GIP and gherkin during the oral glucose tolerance test
P-metabolites and P-lipids after carbohydrate intake6, 12, 24 monthsMetabolomics and lipidomics analyses during the oral glucose tolerance test
Liver fat12 monthsMeasured with MRI
Pancreas fat12 monthsMeasured with MRI
Fat cell size in subcutaneous fat12 months
RNA levels in subcutaneous fat12 monthsRNA sequencing
Forced vital capacity (FVC)12 monthsSpirometry
Forced expiratory volume in 1 s (FEV1)12 monthsSpirometry
Diffusion capacity of the the (DCLO)12 monthsSpirometry
Experiences of the study participantsOnce between 12 and 24 monthsIndividual semi-structured interviews
Erectile function6, 12, 24 monthsOnly men, Erectile function subscale
Prostate symptoms6, 12, 24 monthsOnly men, International prostate symptom score

Countries

Sweden

Contacts

Primary ContactJulia Otten, PhD
julia.otten@umu.se+46703341559

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026